Description: Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. It offers generic pharmaceutical products; and basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances. The company's principal branded pharmaceutical products comprise Copaxone for multiple sclerosis; Provigil and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Azilect for the treatment of Parkinson's disease; Fentora and Actiq for the treatment of pain in opioid-tolerant adult patients with cancer; Amrix for muscle spasm in acute, painful, and musculoskeletal conditions; ProAir for the treatment of bronchial spasms; Qvar for long-term control of chronic bronchial asthma; and Qnasl Nasal Aerosol for seasonal nasal and year-round nasal allergy symptoms. The company also offers Treanda for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma; Tevagrastim/Ratiograstim that stimulate the production of white blood cells; Eporatio, which stimulates the production of red blood cells; Synribo for chronic myeloid leukemia; Plan B One-Step for emergency oral contraception; ParaGard, a non hormonal intrauterine contraceptive; hormone therapies for menopause/perimenopause; Enjuvia for vasomotor symptoms associated with menopause; and therapies for infertility and urinary incontinence. In addition, it produces active pharmaceutical ingredients in the areas of respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company distributes third party products. It has collaborative agreements with Lonza Group Ltd. and OncoGenex Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Home Page: www.tevapharm.com
TEVA Technical Analysis
124 Dvora Hanevi’a Street
Tel Aviv,
6944020
Israel
Phone:
972 3 914 8213
Officers
| Name | Title |
|---|---|
| Mr. Kare Schultz | Pres, CEO & Director |
| Mr. Eliyahu Sharon Kalif | Exec. VP & CFO |
| Mr. Eric Drape | Exec. VP of Global Operations |
| Mr. Mark Sabag | Exec. VP of International Markets Commercial |
| Dr. Sven Dethlefs Ph.D. | Exec. VP of North America Commercial |
| Mr. Amir Weiss | Sr. VP & Chief Accounting Officer |
| Mr. Kevin C. Mannix | Sr. VP of Investor Relations |
| Mr. David M. Stark | Exec. VP & Chief Legal Officer |
| Kathleen Veit | Sr. VP, Global Compliance & Ethics Officer |
| Mr. Eli Shani | Exec. VP of Global Marketing & Portfolio |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 3.6523 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1731 |
| Price-to-Sales TTM: | 0.6493 |
| IPO Date: | 1990-03-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 34713 |